Content

Events
About

Design, Conduct, and Analysis of Clinical Trials in Disease Due to Methicillin-Resistant Staphylococcus Aureus

Given the changing epidemiology of disease due to Staphylococcus aureus (SA), including the emergence of drug-resistant organisms such as methicillin-resistant SA, investigators may wish to evaluatethe effects of antimicrobials in disease due to SA as well as in disease due to other organisms in the same trial. Here JH Powers and TR Fleming discuss issues that investigators should address in trial design, conduct, and analysisto evaluate overall effects or effects within subgroups according tocausative organisms. Download PDF Attachment

Upcoming Events


DigIT Pharma 2026 | AI Commercial, Medical & Patient Care

September 9 - 10, 2026
Steigenberger Airport Hotel Berlin, Deutschland
Register Now | View Agenda | Learn More


Pharmaceutical Launch Excellence Summit US

September 30 - October 1, 2026
Hyatt Regency Boston Harbor, Boston, US
Register Now | View Agenda | Learn More


Pharmaceutical Launch Excellence Summit

1 - 3 December, 2026
Novotel Amsterdam City, Netherlands
Register Now | View Agenda | Learn More

MORE EVENTS